• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • KRASG12C
Enhancing Quality of Life in KRASG12C-Mutated Chemorefractory Metastatic Colorectal Cancer: Insights from the CodeBreaK 300 Phase 3 Trial
Posted inClinical Updates Wellness & Lifestyle

Enhancing Quality of Life in KRASG12C-Mutated Chemorefractory Metastatic Colorectal Cancer: Insights from the CodeBreaK 300 Phase 3 Trial

Posted by By MedXY 09/21/2025
The phase 3 CodeBreaK 300 trial shows sotorasib plus panitumumab improves health-related quality of life and clinical outcomes in KRASG12C-mutated metastatic colorectal cancer compared to standard care.
Read More
Adagrasib vs Docetaxel in KRASG12C-Mutated NSCLC: New Hope from KRYSTAL-12 Phase 3 Trial
Posted inClinical Updates Wellness & Lifestyle

Adagrasib vs Docetaxel in KRASG12C-Mutated NSCLC: New Hope from KRYSTAL-12 Phase 3 Trial

Posted by By MedXY 08/15/2025
The KRYSTAL-12 trial demonstrated that adagrasib significantly improves progression-free survival compared to docetaxel in previously treated KRASG12C-mutated advanced NSCLC, with manageable safety profiles.
Read More
  • Non-β-Lactam Antibiotics, β-Lactam Allergy, and Surgical Site Infections: Implications for Prophylaxis and Stewardship
  • Unraveling the Link Between General Intelligence and Alcohol Use Disorder Risk
  • Deciphering the Role of Intratumoral Microbiota in Breast Cancer: Pathogenesis to Precision Therapeutics
  • Novel Heparanase Inhibitor LMW-DSS Shows Promise in Preventing Breast Cancer Metastasis by Targeting Migration and Angiogenesis
  • Advancing Immunotherapy in Head and Neck Cancer: A Curcumin-Based Polymer Prodrug Nanoplatform Targeting Cancer Stemness and Tumor Microenvironment
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging AI artificial intelligence atrial fibrillation blood pressure breast cancer béo phì cardiovascular health cardiovascular risk clinical trial COPD COVID-19 diabetes diet dinh dưỡng exercise GLP-1 health heart failure Hypertension immunotherapy inflammation MASH mental health metformin Mortality nutrition obesity Pregnancy prevention public health randomized clinical trial randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch thử nghiệm lâm sàng thử nghiệm lâm sàng ngẫu nhiên tirzepatide type 2 diabetes weight loss women's health 心力衰竭

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top